Alzecure: Additional phase IIa data from ACD440 neuropathic pain study - Redeye
Redeye comments on the additional data presented from the phase IIa study with ACD440 in neuropathic pain and reiterate our positive stance to the outcome.
ANNONS
Redeye comments on the additional data presented from the phase IIa study with ACD440 in neuropathic pain and reiterate our positive stance to the outcome.
